Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

BOSTON - Gov. Maura Healey said Friday that it's "absolutely unacceptable" that criminal background checks she ordered last spring at Massachusetts shelters never happened. The Boston Globe ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

BOSTON — Gov. Maura Healey has ordered inspections of state-run homeless shelters after a 28-year-old migrant was arrested at a Revere hotel with a banned ‘assault’ rifle and a stash of ...

BOSTON — Gov. Maura Healey signed a pair of bills Wednesday aimed at lowering prescription drug costs and improving the state’s oversight of hospitals in response to Steward Health Care System ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

However, Denali recently announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.